Mallinckrodt plc Presents Multiple Sclerosis MS Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting MSParis2017
By a
Unresolved relapse may contribute to residual deficits and a progression of disability for diagnosed patients.1,2 H.P. Acthar Gel is
"The management of MS relapse is an ongoing challenge further hampered by the lack of information on the real-world use of various relapse treatments," said
Both analyses were from a single real-world retrospective, observational, cohort study conducted by researchers at Humana Comprehensive Health Insights (CHI) and Mallinckrodt using Humana health insurance administrative claims data. Humana CHI conducted the analyses, which utilized medical and pharmacy claims of adults with MS, ages 18-90, enrolled in Humana Commercial and Medicare Advantage health plans between
Multiple Sclerosis Relapse Treatments and Relapse Resolution: Retrospective Study Results from a
Keywords for this news article include: Neurology, Managed Care, Neuroimmunology,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
National Center for Scientific Research (CNRS) Reports Findings in Risk Management (Toward Probabilistic Prediction of Flash Flood Human Impacts)
The Miller Law Firm Recovers over $18,000,000 for Six Oakland Homeowners Associations with Construction Defects
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News